Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Twist Bioscience Corporation, Gilead Sciences or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Twist Bioscience Corporation, Gilead Sciences and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Twist Bioscience Corporation, Gilead Sciences and Inc.

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.

Latest Biotechnology and Twist Bioscience Corporation, Gilead Sciences, Inc. Stock News

As of September 22, 2026, Twist Bioscience Corporation had a $10.3 billion market capitalization, compared to the Biotechnology median of $271.9 million. Twist Bioscience Corporation’s stock is up 399.5% in 2026, up 10.7% in the previous five trading days and up 490.18% in the past year.

Currently, Twist Bioscience Corporation does not have a price-earnings ratio. Twist Bioscience Corporation’s trailing 12-month revenue is $431.8 million with a -31.7% net profit margin. Year-over-year quarterly sales growth most recently was 23.2%. Analysts expect adjusted earnings to reach $-0.600 per share for the current fiscal year. Twist Bioscience Corporation does not currently pay a dividend.

As of September 22, 2026, Gilead Sciences, Inc. had a $189.3 billion market cap, putting it in the 99th percentile of all stocks. Gilead Sciences, Inc.’s stock is up 23.8% in 2026, up 2.9% in the previous five trading days and up 33.82% in the past year.

Currently, Gilead Sciences, Inc. does not have a price-earnings ratio. Gilead Sciences, Inc.’s trailing 12-month revenue is $30.5 billion with a -10.6% net profit margin. Year-over-year quarterly sales growth most recently was 10.2%. Analysts expect adjusted earnings to reach $-0.426 per share for the current fiscal year. Gilead Sciences, Inc. currently has a 2.1% dividend yield.

How We Compare Twist Bioscience Corporation, Gilead Sciences and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Twist Bioscience Corporation, Gilead Sciences and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Twist Bioscience Corporation, Gilead Sciences and Inc. Stock Value Grades

Company	Ticker	Value
Twist Bioscience Corporation	TWST	F
Gilead Sciences, Inc.	GILD	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Twist Bioscience Corporation has a Value Score of 4, which is Ultra Expensive. Gilead Sciences, Inc. has a Value Score of 27, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither Twist Bioscience Corporation, Gilead Sciences or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Twist Bioscience Corporation, Gilead Sciences or Inc. is the better investment when it comes to value.

Twist Bioscience Corporation, Gilead Sciences and Inc. Growth Grades

Company	Ticker	Growth
Twist Bioscience Corporation	TWST	D
Gilead Sciences, Inc.	GILD	C

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Twist Bioscience Corporation has a Growth Score of 28, which is Weak. Gilead Sciences, Inc. has a Growth Score of 56, which is Average.

The Growth Stock Winner: No Clear Winner

Neither Twist Bioscience Corporation, Gilead Sciences or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Twist Bioscience Corporation, Gilead Sciences or Inc. is the better investment when it comes to sustainable growth.

Twist Bioscience Corporation, Gilead Sciences and Inc.’s Momentum Grades

Company	Ticker	Momentum
Twist Bioscience Corporation	TWST	A
Gilead Sciences, Inc.	GILD	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Twist Bioscience Corporation has a Momentum Score of 99, which is Very Strong. Gilead Sciences, Inc. has a Momentum Score of 78, which is Strong.

The Momentum Grade Winner: Twist Bioscience Corporation

As you can clearly see from the Momentum Grade breakdown above, Twist Bioscience Corporation is considered to have stronger momentum compared to Gilead Sciences, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Twist Bioscience Corporation could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Twist Bioscience Corporation, Gilead Sciences and Inc. Grades

In addition to Momentum, Growth and Value, A+ Investor also provides grades for Estimate Revisions and Quality.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Twist Bioscience Corporation, Gilead Sciences and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Twist Bioscience Corporation, Gilead Sciences or Inc. Stock?

Overall, Twist Bioscience Corporation stock has a Value Score of 4, Growth Score of 28 and Momentum Score of 99.

Gilead Sciences, Inc. stock has a Value Score of 27, Growth Score of 56 and Momentum Score of 78.

Comparing Twist Bioscience Corporation, Gilead Sciences and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.